Cargando cotizaciones...
Previsión
El precio objetivo medio de los analistas es de 18,99€ (+34,87%). La mediana es de 17,59€ (+24,93%).
| Comprar |
10 |
| Mantener |
2 |
| Vender |
0 |
Noticias Ir al feed de noticias
Immunic advances vidofludimus calcium toward Phase 3 readouts, expects data by year-end
Immunic said its Phase 3 ENSURE-1 and ENSURE-2 trials of vidofludimus calcium in relapsing MS remain on track to deliver top-line data by the end of 2026, with a potential US NDA submission in mid-2027 and a regulatory decision targeted for 2028 if results are positive. The company plans to start a Phase 3 program in progressive MS later this year following supportive Phase 2 CALLIPER analyses. In Q2, operating expenses rose to $35.3 million and net loss widened to about $34.1 million; cash and equivalents totaled $155.1 million, which management expects to fund operations into late 2027. Immunic also strengthened its leadership and board ahead of potential commercialization. » Más en finance.yahoo.com
Datos financieros de la empresa
| (EUR) | jun 2026 | |
|---|---|---|
| Ingresos | 0,00 | - |
| Beneficio bruto | 0,00 | - |
| Beneficio neto | −29,88M | 31,30% |
| EBITDA | −29,79M | 31,13% |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 191,93M€ |
Número de acciones | 13,62M |
Máximo/mínimo de 52 semanas | 14,96€ - 4,34€ |
| Dividendos | No |
Beta | 1,4 |
Ratio P/E | −3,42 |
Ratio PEG | −0,04 |
Ratio P/B | 5,47 |
Ratio P/S | 0,00 |
Perfil de la empresa
| Nombre | Immunic |
| CEO | Erik Lundgren |
| Empleados | 95 |
Descubrir activos
Los accionistas de Immunic también invierten en los siguientes activos
